These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 37598924)

  • 21. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway.
    Huang C; Zhou T; Ma L; Zhao S
    Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized, double-blind, phase two study of ruxolitinib plus regorafenib in patients with relapsed/refractory metastatic colorectal cancer.
    Fogelman D; Cubillo A; García-Alfonso P; Mirón MLL; Nemunaitis J; Flora D; Borg C; Mineur L; Vieitez JM; Cohn A; Saylors G; Assad A; Switzky J; Zhou L; Bendell J
    Cancer Med; 2018 Nov; 7(11):5382-5393. PubMed ID: 30123970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new herbal formula BP10A exerted an antitumor effect and enhanced anticancer effect of irinotecan and oxaliplatin in the colon cancer PDTX model.
    Kim J; Kim HY; Hong S; Shin S; Kim YA; Kim NS; Bang OS
    Biomed Pharmacother; 2019 Aug; 116():108987. PubMed ID: 31112870
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Regorafenib suppresses epidermal growth factor receptor signaling-modulated progression of colorectal cancer.
    Liu YC; Tsai JJ; Weng YS; Hsu FT
    Biomed Pharmacother; 2020 Aug; 128():110319. PubMed ID: 32502841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Curcumin enhances the effects of irinotecan on colorectal cancer cells through the generation of reactive oxygen species and activation of the endoplasmic reticulum stress pathway.
    Huang YF; Zhu DJ; Chen XW; Chen QK; Luo ZT; Liu CC; Wang GX; Zhang WJ; Liao NZ
    Oncotarget; 2017 Jun; 8(25):40264-40275. PubMed ID: 28402965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
    Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
    Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selenoprotein S silencing triggers mouse hepatoma cells apoptosis and necrosis involving in intracellular calcium imbalance and ROS-mPTP-ATP.
    Li X; Chen M; Yang Z; Wang W; Lin H; Xu S
    Biochim Biophys Acta Gen Subj; 2018 Oct; 1862(10):2113-2123. PubMed ID: 30017912
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regorafenib and Ruthenium Complex Combination Inhibit Cancer Cell Growth by Targeting PI3K/AKT/ERK Signalling in Colorectal Cancer Cells.
    Sharma D; Rasool F; Bharti M; Vyas KM; Magani SKJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36614133
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EVs delivery of miR-1915-3p improves the chemotherapeutic efficacy of oxaliplatin in colorectal cancer.
    Xiao Z; Liu Y; Li Q; Liu Q; Liu Y; Luo Y; Wei S
    Cancer Chemother Pharmacol; 2021 Dec; 88(6):1021-1031. PubMed ID: 34599680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer.
    Belli V; Sforza V; Cardone C; Martinelli E; Barra G; Matrone N; Napolitano S; Morgillo F; Tuccillo C; Federico A; Dallio M; Loguercio C; Gravina AG; De Palma R; Ciardiello F; Troiani T
    Oncotarget; 2017 Sep; 8(40):68305-68316. PubMed ID: 28978118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genipin Enhances the Therapeutic Effects of Oxaliplatin by Upregulating BIM in Colorectal Cancer.
    Kim BR; Jeong YA; Jo MJ; Park SH; Na YJ; Kim JL; Jeong S; Yun HK; Kang S; Lee DH; Oh SC
    Mol Cancer Ther; 2019 Apr; 18(4):751-761. PubMed ID: 30787174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-Associated Macrophages Promote Oxaliplatin Resistance
    Lan H; Liu Y; Liu J; Wang X; Guan Z; Du J; Jin K
    Mol Pharm; 2021 Mar; 18(3):1026-1037. PubMed ID: 33555197
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model.
    Abou-Elkacem L; Arns S; Brix G; Gremse F; Zopf D; Kiessling F; Lederle W
    Mol Cancer Ther; 2013 Jul; 12(7):1322-31. PubMed ID: 23619301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Zhang YK; Wang YJ; Lei ZN; Zhang GN; Zhang XY; Wang DS; Al-Rihani SB; Shukla S; Ambudkar SV; Kaddoumi A; Shi Z; Chen ZS
    Cancer Lett; 2019 Feb; 442():104-112. PubMed ID: 30392788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of tNOX expression through the ROS-p53-POU3F2 axis contributes to cellular responses against oxaliplatin in human colon cancer cells.
    Chen HY; Islam A; Yuan TM; Chen SW; Liu PF; Chueh PJ
    J Exp Clin Cancer Res; 2018 Jul; 37(1):161. PubMed ID: 30029680
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Combination Therapy for Human Oxaliplatin-resistant Colorectal Cancer Using Oxaliplatin and Coxsackievirus A11.
    Wang B; Ogata H; Takishima Y; Miyamoto S; Inoue H; Kuroda M; Yamada K; Hijikata Y; Murahashi M; Shimizu H; Okazaki T; Nakanishi Y; Tani K
    Anticancer Res; 2018 Nov; 38(11):6121-6126. PubMed ID: 30396927
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sirtuin 3 silencing improves oxaliplatin efficacy through acetylation of MnSOD in colon cancer.
    Torrens-Mas M; Hernández-López R; Oliver J; Roca P; Sastre-Serra J
    J Cell Physiol; 2018 Aug; 233(8):6067-6076. PubMed ID: 29323702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sophocarpine can enhance the inhibiting effect of oxaliplatin on colon cancer liver metastasis-in vitro and in vivo.
    Yang YS; Wen D; Zhao XF
    Naunyn Schmiedebergs Arch Pharmacol; 2021 Jun; 394(6):1263-1274. PubMed ID: 33409556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel coordination complex of platinum (PT) induces cell death in colorectal cancer by altering redox balance and modulating MAPK pathway.
    Al-Khayal K; Vaali-Mohammed MA; Elwatidy M; Bin Traiki T; Al-Obeed O; Azam M; Khan Z; Abdulla M; Ahmad R
    BMC Cancer; 2020 Jul; 20(1):685. PubMed ID: 32703189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.